Overview

Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety of natalizumab use in the pediatric multiple sclerosis (MS) population.
Details
Lead Sponsor:
Biogen
Treatments:
Natalizumab